Regeneron and Roche's antibody cocktail has been accepted by the FDA as a high priority for approval as prophylaxis and for non-hospitalized COVID-19 patients.

Press release:

https://investor.regeneron.com/news-releases/news-release-details/fda-accepts-regen-covr-casirivimab-and-imdevimab-priority-review